Umbralisib Shows Promise in Relapsed/Refractory Marginal Zone Lymphoma Umbralisib Shows Promise in Relapsed/Refractory Marginal Zone Lymphoma

Umbralisib, an investigational oral inhibitor of PI3K-delta, has significant activity against relapsed/refractory marginal-zone lymphoma (MZL) and manageable side effects, according to early results from an ongoing phase 2b trial.Reuters Health Information
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news